|Study Description:||The goal of Part I of this clinical research study is to learn the highest |
tolerable dose of PRI-724 that can be given to patients with acute advanced
myeloid cancer. Acute means one of the following disease types: advanced acute
myeloid leukemia, myelodysplastic syndrome, or accelerated phase chronic
myeloid leukemia. Together, participants with these diseases make up the Acute
The goal of Part II of this clinical research study is to learn the highest
tolerable dose of PRI-724 that can be given to patients with chronic myeloid
leukemia. These participants make up the "Non-Acute Group.”
In Part III, researchers will study the safety of PRI-724 combined with a
standard drug, dasatinib or cytarabine. Part III includes participants in both
the Acute and Non-Acute Groups. Researchers also want to learn if PRI-724
combined with dasatinib can help to control CML, and if PRI-724 combined with
cytarabine can help control AML in patients age 65 years or older.
PRI-724 is designed to keep cancer cells from sending and receiving signals
that they need to grow and spread.